A Facchin1,2,3, V Elie1, N Benyoub1, S Magreault1, A Maisin4, T Storme5, W Zhao6,7, G Deschenes4, E Jacqz-Aigrain8,9. 1. Département de Pharmacologie Pédiatrique et Pharmacogénétique, CHU Robert Debré APHP, Paris, France. 2. Service de Pharmacie, Centre hospitalier Intercommunal Robert Ballanger, Aulnay-Sous-Bois, France. 3. Université de Paris, Ecole Doctorale MTCI, Paris, France. 4. Service de Néphrologie pédiatrique, Hôpital Robert Debré, APHP, Paris, France. 5. Service de Pharmacie, CHU Robert Debré APHP, Paris, France. 6. Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China. 7. Paediatric Research Institute, Children's Hospital of Hebei Province affiliated to Hebei Medical University, Shijiazhuang, China. 8. Département de Pharmacologie Pédiatrique et Pharmacogénétique, CHU Robert Debré APHP, Paris, France evelyne.jacqz-aigrain@aphp.fr evelyne.jacqzaigrain@gmail.com. 9. Université de Paris, Paris, France.
Abstract
BACKGROUND: Valganciclovir, the ganciclovir prodrug, is an antiviral agent administered orally to prevent or treat cytomegalovirus infection in solid organ transplant recipients. Dosing regimen of valganciclovir is still controversial in children, as the number of patients reaching the Area Under the Curve at steady state (AUCss) target (40 - 60 mg.h/L) remains highly variable. The aim of this study was to determine the population pharmacokinetics of valganciclovir in paediatric renal transplant recipients and propose an appropriate dosing regimen. METHODS: Renal transplant children who received valganciclovir to prevent or treat cytomegalovirus infection at Robert Debré University Hospital were included. Plasma ganciclovir concentrations were determined by high performance liquid chromatography and ultraviolet detection. Population pharmacokinetic analysis was performed with NONMEM software. RESULTS: 104 patients, aged 2 to 20 years, treated with valganciclovir administered at a mean dose of 17.3 ± 6.1 mg/kg to prevent and/or treat cytomegalovirus infection after renal transplantation were included. A total of 1212 samples were available. A two-compartment model with first-order elimination best fitted the data: ganciclovir clearance increased with body surface area, was 15% higher in boys and decreased with increasing creatinine concentration. Central volume of distribution increased with body surface area and was 14% higher in boys. According to the personalized dosing regimen, 65.7% and 65.4% of children were predicted to achieve the AUCss target for cytomegalovirus prophylaxis and treatment, respectively. CONCLUSION: A new pharmacokinetic model was built allowing to propose individualised dose adapted to renal transplanted paediatric patients characteristics.
BACKGROUND:Valganciclovir, the ganciclovir prodrug, is an antiviral agent administered orally to prevent or treat cytomegalovirus infection in solid organ transplant recipients. Dosing regimen of valganciclovir is still controversial in children, as the number of patients reaching the Area Under the Curve at steady state (AUCss) target (40 - 60 mg.h/L) remains highly variable. The aim of this study was to determine the population pharmacokinetics of valganciclovir in paediatric renal transplant recipients and propose an appropriate dosing regimen. METHODS: Renal transplant children who received valganciclovir to prevent or treat cytomegalovirus infection at Robert Debré University Hospital were included. Plasma ganciclovir concentrations were determined by high performance liquid chromatography and ultraviolet detection. Population pharmacokinetic analysis was performed with NONMEM software. RESULTS: 104 patients, aged 2 to 20 years, treated with valganciclovir administered at a mean dose of 17.3 ± 6.1 mg/kg to prevent and/or treat cytomegalovirus infection after renal transplantation were included. A total of 1212 samples were available. A two-compartment model with first-order elimination best fitted the data: ganciclovir clearance increased with body surface area, was 15% higher in boys and decreased with increasing creatinine concentration. Central volume of distribution increased with body surface area and was 14% higher in boys. According to the personalized dosing regimen, 65.7% and 65.4% of children were predicted to achieve the AUCss target for cytomegalovirus prophylaxis and treatment, respectively. CONCLUSION: A new pharmacokinetic model was built allowing to propose individualised dose adapted to renal transplanted paediatric patients characteristics.
Authors: A Asberg; A Humar; H Rollag; A G Jardine; H Mouas; M D Pescovitz; D Sgarabotto; M Tuncer; I L Noronha; A Hartmann Journal: Am J Transplant Date: 2007-07-19 Impact factor: 8.086
Authors: Hugh Wiltshire; Carlos V Paya; Mark D Pescovitz; Atul Humar; Edward Dominguez; Kenneth Washburn; Emily Blumberg; Barbara Alexander; Richard Freeman; Nigel Heaton; Klaas P Zuideveld Journal: Transplantation Date: 2005-06-15 Impact factor: 4.939
Authors: M D Pescovitz; R B Ettenger; C F Strife; J R Sherbotie; S E Thomas; S McDiarmid; S Bartosh; J Ives; M R Bouw; J Bucuvalas Journal: Transpl Infect Dis Date: 2009-12-04 Impact factor: 2.228
Authors: T Nguyen; M Oualha; C Briand; M Bendavid; A Béranger; S Benaboud; J-M Tréluyer; Y Zheng; F Foissac; S Winter; I Gana; S Boujaafar; V Lopez; R Berthaud; Z Demir; N Bouazza; D Hirt Journal: Antimicrob Agents Chemother Date: 2021-02-17 Impact factor: 5.191